Published in J Antimicrob Chemother on September 10, 2007
Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev (2010) 2.32
A novel tumor necrosis factor-mediated mechanism of direct epithelial sodium channel activation. Am J Respir Crit Care Med (2014) 1.55
Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema. Proc Natl Acad Sci U S A (2012) 1.14
Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm (2013) 1.01
Protein kinase C-α and arginase I mediate pneumolysin-induced pulmonary endothelial hyperpermeability. Am J Respir Cell Mol Biol (2012) 0.99
Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm (2012) 0.95
Antivirulence activity of azithromycin in Pseudomonas aeruginosa. Front Microbiol (2014) 0.90
Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs. Toxins (Basel) (2013) 0.85
Macrolides and β-lactam antibiotics enhance C3b deposition on the surface of multidrug-resistant Streptococcus pneumoniae strains by a LytA autolysin-dependent mechanism. Antimicrob Agents Chemother (2012) 0.81
Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction. Front Physiol (2014) 0.80
Arginase 1: an unexpected mediator of pulmonary capillary barrier dysfunction in models of acute lung injury. Front Immunol (2013) 0.80
Pneumolysin activates neutrophil extracellular trap formation. Clin Exp Immunol (2016) 0.79
Pneumococcal Pneumolysin Induces DNA Damage and Cell Cycle Arrest. Sci Rep (2016) 0.78
Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study. BMJ Open (2013) 0.77
Levofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin. Antimicrob Agents Chemother (2014) 0.76
Beneficial and Harmful Interactions of Antibiotics with Microbial Pathogens and the Host Innate Immune System. Pharmaceuticals (Basel) (2010) 0.75
Prevalence, pathogenesis, therapy, and prevention of cardiovascular events in patients with community-acquired pneumonia. Pneumonia (Nathan) (2016) 0.75
Epithelial Sodium Channel-α Mediates the Protective Effect of the TNF-Derived TIP Peptide in Pneumolysin-Induced Endothelial Barrier Dysfunction. Front Immunol (2017) 0.75
Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol (2001) 6.66
Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis (2000) 4.24
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol (2001) 4.19
Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis (1999) 3.72
Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet (1992) 3.42
Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med (2000) 3.09
Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins. Annu Rev Microbiol (1993) 3.09
Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun (1994) 3.01
Microarray-based identification of a novel Streptococcus pneumoniae regulon controlled by an autoinduced peptide. J Bacteriol (2000) 2.85
Pulmonary echinococcosis. Eur Respir J (2003) 2.80
A reevaluation of sputum microscopy and culture in the diagnosis of pulmonary tuberculosis. Chest (1989) 2.76
Host cellular immune response to pneumococcal lung infection in mice. Infect Immun (2000) 2.74
Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes. Infect Immun (1994) 2.49
The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a type 2 pneumococcus. J Infect Dis (1995) 2.47
Genetic diversity of penicillin-binding protein 2B and 2X genes from Streptococcus pneumoniae in South Africa. Antimicrob Agents Chemother (1993) 2.44
Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun (1991) 2.32
Structure and function of pneumolysin, the multifunctional, thiol-activated toxin of Streptococcus pneumoniae. Mol Microbiol (1991) 2.11
A neuraminidase from Streptococcus pneumoniae has the features of a surface protein. Infect Immun (1994) 2.04
Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis (2000) 2.02
Alterations in PBP 1A essential-for high-level penicillin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 1.98
Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut (1986) 1.93
Pneumolysin, the thiol-activated toxin of Streptococcus pneumoniae, does not require a thiol group for in vitro activity. Infect Immun (1989) 1.91
Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis (2007) 1.87
Lack of utility of serotyping multiple colonies for detection of simultaneous nasopharyngeal carriage of different pneumococcal serotypes. Pediatr Infect Dis J (2000) 1.87
Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains. Infect Immun (2001) 1.86
Alterations in penicillin-binding protein 2B from penicillin-resistant wild-type strains of Streptococcus pneumoniae. Antimicrob Agents Chemother (1995) 1.82
Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest (1995) 1.77
Spread of the Spanish multi-resistant serotype 23F clone of Streptococcus pneumoniae to Seoul, Korea. Microb Drug Resist (1997) 1.74
Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect Immun (1995) 1.72
Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia. Clin Infect Dis (2011) 1.70
Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J (2000) 1.69
Role of manganese-containing superoxide dismutase in oxidative stress and virulence of Streptococcus pneumoniae. Infect Immun (2000) 1.69
Evaluation of the Etest as a means of determining the antibiotic susceptibilities of isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in the Central African Republic. J Antimicrob Chemother (2000) 1.67
Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 1.66
Effect of Streptococcus pneumoniae on human respiratory epithelium in vitro. Infect Immun (1989) 1.64
Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo. Am J Respir Cell Mol Biol (1991) 1.64
Proinflammatory interactions of pneumolysin with human neutrophils. J Infect Dis (2001) 1.62
Growth of Clostridium difficile and production of toxins A and B in complex and defined media. J Med Microbiol (1986) 1.62
Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm(B) and mef(A)) in South Africa. Antimicrob Agents Chemother (2001) 1.60
Clinical and nasopharyngeal isolates of unusual multiply resistant pneumococci. Am J Dis Child (1986) 1.55
Streptococcus pneumoniae: virulence factors and variation. Clin Microbiol Infect (2010) 1.55
Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr (2000) 1.54
Community-acquired pneumonia due to penicillin-resistant pneumococci. N Engl J Med (1985) 1.54
Laboratory-based diagnosis of pneumococcal pneumonia: state of the art and unmet needs. Clin Microbiol Infect (2011) 1.54
Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply. Vaccine (1998) 1.51
Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child (1992) 1.49
Patterns of cytokine expression in community-acquired pneumonia. Chest (1995) 1.46
Guideline for the management of acute asthma in adults: 2013 update. S Afr Med J (2012) 1.46
'Atypical' bacteria are a common cause of community-acquired pneumonia in hospitalised adults. S Afr Med J (1994) 1.46
Three predominant clones identified within penicillin-resistant South African isolates of Streptococcus pneumoniae. Microb Drug Resist (1997) 1.45
Differentiation of sarcoidosis from tuberculosis using an enzyme-linked immunosorbent assay for the detection of antibodies against Mycobacterium tuberculosis. Chest (1988) 1.42
A two-component system that controls the expression of pneumococcal surface antigen A (PsaA) and regulates virulence and resistance to oxidative stress in Streptococcus pneumoniae. Mol Microbiol (2004) 1.42
Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in southern Israel. J Infect Dis (1998) 1.42
In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus. Antimicrob Agents Chemother (1996) 1.42
Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. Bull World Health Organ (2006) 1.41
Interaction of pneumolysin-sufficient and -deficient isogenic variants of Streptococcus pneumoniae with human respiratory mucosa. Infect Immun (1995) 1.41
Alterations in MurM, a cell wall muropeptide branching enzyme, increase high-level penicillin and cephalosporin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 1.40
Relative roles of pneumolysin and hydrogen peroxide from Streptococcus pneumoniae in inhibition of ependymal ciliary beat frequency. Infect Immun (2000) 1.40
Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J (2006) 1.40
Enzyme-linked immunosorbent assay for the detection of antibodies against Mycobacterium tuberculosis in bronchial washings and serum. Chest (1988) 1.39
Distinct roles for pneumolysin's cytotoxic and complement activities in the pathogenesis of pneumococcal pneumonia. Am J Respir Crit Care Med (1996) 1.38
Relation of vessel wall shear stress to atherosclerosis progression in human coronary arteries. Arterioscler Thromb (1993) 1.38
Abdominal findings in AIDS-related pulmonary tuberculosis correlated with associated CD4 levels. Abdom Imaging (1999) 1.38
The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in vitro. Microb Pathog (1990) 1.37
A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs. Infect Immun (1997) 1.36
Amino acid changes affecting the activity of pneumolysin alter the behaviour of pneumococci in pneumonia. Microb Pathog (1998) 1.35
Pneumolysin is the main inducer of cytotoxicity to brain microvascular endothelial cells caused by Streptococcus pneumoniae. Infect Immun (2001) 1.35
Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. J Infect Dis (2000) 1.33
Mutations in ribosomal protein L16 conferring reduced susceptibility to evernimicin (SCH27899): implications for mechanism of action. Antimicrob Agents Chemother (2000) 1.32
Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J (1998) 1.32
A conserved tryptophan in pneumolysin is a determinant of the characteristics of channels formed by pneumolysin in cells and planar lipid bilayers. Biochem J (1998) 1.30
The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses. Infect Immun (2000) 1.28
The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. Br J Rheumatol (1992) 1.27
Long-term survival of Streptococcus pneumoniae at room temperature on Dorset egg medium. J Clin Microbiol (1998) 1.26
Rapid detection of penicillin-resistant Streptococcus pneumoniae in cerebrospinal fluid by a seminested-PCR strategy. J Clin Microbiol (1998) 1.26
Non-Penicillin-Binding protein mediated high-level penicillin and cephalosporin resistance in a Hungarian clone of Streptococcus pneumoniae. Microb Drug Resist (2000) 1.24
Molecular basis of rifampin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 1.24
Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. Clin Infect Dis (1997) 1.23
Association between chloroform levels in finished drinking water supplies and various site-specific cancer mortality rates. J Environ Pathol Toxicol (1979) 1.23
The molecular mechanism of pneumolysin, a virulence factor from Streptococcus pneumoniae. J Mol Biol (1998) 1.20
Carriage of penicillin resistant pneumococci. Arch Dis Child (1986) 1.20
Evernimicin (SCH27899) inhibits a novel ribosome target site: analysis of 23S ribosomal DNA mutants. Antimicrob Agents Chemother (2000) 1.19
Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother (2001) 1.18
"Megaprimer" method of PCR-based mutagenesis: the concentration of megaprimer is a critical factor. Biotechniques (1997) 1.18
The Ami-AliA/AliB permease of Streptococcus pneumoniae is involved in nasopharyngeal colonization but not in invasive disease. Infect Immun (2004) 1.17
Emergence of the M phenotype of erythromycin-resistant pneumococci in South Africa. Emerg Infect Dis (1998) 1.17
Identification of the tetracycline resistance gene, tet(O), in Streptococcus pneumoniae. Antimicrob Agents Chemother (1996) 1.16
Self-interaction of pneumolysin, the pore-forming protein toxin of Streptococcus pneumoniae. J Mol Biol (1998) 1.16
Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J (2005) 1.16
An increased familial frequency of gallstones. Gastroenterology (1983) 1.13
Pneumolysin activates phospholipase A in pulmonary artery endothelial cells. Infect Immun (1994) 1.13
Extrapolation of the relative risk of radiogenic neoplasms across mouse strains and to man. Radiat Res (1988) 1.13
Clostridium difficile--a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis. J Med Microbiol (1987) 1.13
The hemagglutination-inhibition assay for erythropoietin. Its specificity, reproducibility and sensitivity. Isr J Med Sci (1971) 1.13
Delta 32 deletion of CCR5 gene and association with asthma or atopy. Lancet (2000) 1.12
The dose-response relationship for ethyl methanesulfonate-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in Chinese hamster ovary cells. Somatic Cell Genet (1975) 1.12
Role of two-component systems in the virulence of Streptococcus pneumoniae. J Med Microbiol (2006) 1.12